Yu Yuan, Qin Xuemei, Yan Shuxin, Wang Wenxia, Sun Yanlin, Zhang Maohong
Department of Hematology, Qilu Hospital, Shandong University, Jinan, People's Republic of China.
Department of Gynecology, Qilu Hospital, Shandong University, Jinan, People's Republic of China.
Onco Targets Ther. 2015 Dec 10;8:3707-13. doi: 10.2147/OTT.S92815. eCollection 2015.
Myeloid sarcoma (MS) is defined as a tumor mass consisting of myeloid blast with or without maturation occurring at an anatomical site other than bone marrow with normal architectural effacement. It can also precede the onset of leukemia which is called non-leukemic MS. Non-leukemic MS is a kind of rare disease and easy to be misdiagnosed as other common malignancies due to the rarity and nonspecific manifestation. We herein report an unusual case of non-leukemic MS involving the vulva, vagina, and cervix in a female patient. The bone marrow aspiration and biopsy of the patient revealed no hematological abnormality. Immunohistochemical staining of the biopsies was strongly positive for myeloperoxidase, CD68, leukocyte common antigen (LCA), CD117, CD34, CD38, CD79a, and negative for cytokeratin (CK), epithelial memberane antigen (EMA), CD2, CD3, CD20, CD5, CD138. Then a diagnosis of non-leukemic MS was made. Unfortunately, our patient received only one cycle of chemotherapy consisting of cytosine arabinoside and daunorubicin, then refused any further treatment and died 4 months after diagnosis. Although systemic chemotherapy is widely accepted to be a promising strategy, its benefit still needs to be further assessed. Certain questions still need to be answered for this disease: 1) Why can approximately 20% of the patients with non-leukemic MS remain disease-free after local therapy alone? 2) How many cycles of chemotherapy are needed for these patients after achievement of complete remission? 3) What are the prognostic or risk factors in these patients who have no abnormality of karyotype, fusion genes, or gene mutation to predict responsiveness to chemotherapy and outcome? 4) What is the risk factor for relapse? The rarity of non-leukemic MS makes it almost impossible to conduct large-scale randomized trials, but judicious study for each patient with MS is helpful for a further understanding of the nature of the disease.
髓系肉瘤(MS)被定义为一种肿瘤块,由髓母细胞组成,有或无成熟现象,发生于骨髓以外的解剖部位,且正常结构消失。它也可先于白血病发病,称为非白血病性MS。非白血病性MS是一种罕见疾病,由于其罕见性和非特异性表现,容易被误诊为其他常见恶性肿瘤。我们在此报告一例不寻常的非白血病性MS病例,累及一名女性患者的外阴、阴道和宫颈。该患者的骨髓穿刺和活检未发现血液学异常。活检组织的免疫组化染色显示髓过氧化物酶、CD68、白细胞共同抗原(LCA)、CD117、CD34、CD38、CD79a呈强阳性,细胞角蛋白(CK)、上皮膜抗原(EMA)、CD2、CD3、CD20、CD5、CD138呈阴性。随后做出了非白血病性MS的诊断。不幸的是,我们的患者仅接受了一个周期由阿糖胞苷和柔红霉素组成的化疗,然后拒绝任何进一步治疗,诊断后4个月死亡。尽管全身化疗被广泛认为是一种有前景的策略,但其益处仍需进一步评估。对于这种疾病仍有一些问题需要解答:1)为什么约20%的非白血病性MS患者仅接受局部治疗后就能保持无病状态?2)这些患者达到完全缓解后需要多少周期的化疗?3)在这些核型、融合基因或基因突变无异常的患者中,预测化疗反应性和预后的预后或风险因素是什么?4)复发的风险因素是什么?非白血病性MS的罕见性使得几乎不可能进行大规模随机试验,但对每例MS患者进行审慎研究有助于进一步了解该疾病的本质。